Company news
Marvell Technology, Inc. (NASDAQ:MRVL) news
Every Marvell Technology, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Marvell to Showcase End-to-End AI Data Center Connectivity Portfolio at AI Infra Summit 2026
September 9, 2026
Marvell Technology, Inc. Reports Second Quarter of Fiscal Year 2027 Financial Results
August 27, 2026
Marvell Technology, Inc. Announces Conference Call to Review Second Quarter of Fiscal Year 2027 Financial Results
August 4, 2026
Marvell to Showcase Advanced AI Memory and Storage Infrastructure Portfolio for Agentic AI Inference at FMS 2026
August 3, 2026
Marvell to Invest $250 Million in India, Expanding Bangalore Facility to Drive Next-generation AI Technology Development
July 29, 2026
Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
June 5, 2026
Marvell Announces Availability of Industry’s First 102.4 Tbps Switch Purpose-Built for AI and Cloud Data Center Infrastructure
June 1, 2026
Marvell Technology, Inc. Reports First Quarter of Fiscal Year 2027 Financial Results
May 27, 2026
Marvell Keynote at COMPUTEX 2026: The Future of AI Scaling Depends on Connectivity
May 26, 2026
Marvell Technology, Inc. Announces Conference Call to Review First Quarter of Fiscal Year 2027 Financial Results
May 4, 2026
POET Technologies Provides Purchase Order Update
April 27, 2026
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
April 23, 2026
Marvell Announces Acquisition of Polariton Technologies, Advancing Optical Performance Scaling to 3.2T and Beyond
April 22, 2026
Marvel Biosciences Announces Closing of Convertible Debenture Offering
April 17, 2026
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
April 16, 2026
Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering
April 13, 2026
Marvel Biosciences Announces Proposed Convertible Debenture Offering
April 8, 2026
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
April 7, 2026
NVIDIA AI Ecosystem Expands as Marvell Joins Forces Through NVLink Fusion
March 31, 2026
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
March 30, 2026
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
March 25, 2026
Matt Murphy, Marvell Chairman and CEO, to Keynote at COMPUTEX 2026
March 19, 2026
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
March 18, 2026
Marvell Launches Next-generation CXL Switch, Enabling Memory Pooling to Break Through the AI "Memory Wall"
March 17, 2026
Marvell Launches Next-generation CXL Switch, Enabling Memory Pooling to Break Through the AI “Memory Wall”
March 17, 2026
Marvell Launches Industry’s First 260-lane PCIe 6.0 Switch for AI Data Center Scale-up Infrastructure
March 17, 2026
Marvell and Lumentum to Demonstrate Optical Circuit Switching for Next-generation AI Scale-up Infrastructure
March 16, 2026
Marvell Ushers In the 1.6T Era with Expanded Optical DSP Platform Portfolio, Redefining AI Data Center End-to-End Connectivity
March 12, 2026
Marvell to Showcase Industry-leading, End-to-End Connectivity Solutions for AI Data Center Infrastructure at OFC 2026
March 12, 2026
Marvell and Mojo Vision Collaborate to Develop Next-generation, High-density Micro-LED Connectivity Solutions
March 12, 2026
Marvell Technology : Annual Report for Fiscal Year Ending January 31, 2026 (Form 10-K)
March 11, 2026
Marvell Technology, Inc. Reports Fourth Quarter and Fiscal Year 2026 Financial Results
March 5, 2026
Marvell Extends ZR/ZR+ Leadership with Industry-first 1.6T ZR/ZR+ Pluggable and 2nm Coherent DSPs for Secure AI Scale-across Interconnects
March 5, 2026
Marvel Biosciences Sponsors Scientific Meeting on Purines
March 4, 2026
Marvell to Showcase PCIe 8.0 SerDes Demonstration at DesignCon 2026
February 24, 2026
Marvell to Showcase Latest AI Data Center Connectivity Solutions at DesignCon 2026
February 24, 2026
Marvel Biosciences Announces Grant of Deferred Share Units
February 18, 2026
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
February 18, 2026
Marvell Completes Acquisition of XConn Technologies
February 10, 2026
Marvell Technology, Inc. Announces Conference Call to Review Fourth Fiscal Quarter and Fiscal Year 2026 Financial Results
February 9, 2026
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
February 3, 2026
Marvell Completes Acquisition of Celestial AI
February 2, 2026
Marvell to Acquire XConn Technologies, Expanding Leadership in AI Data Center Connectivity
January 6, 2026
Marvell Technology, Inc. Declares Quarterly Dividend Payment
December 12, 2025
Marvell Launches Strategic Initiative to Accelerate AEC Ecosystem and Hyperscaler Adoption
December 9, 2025
Marvell Announces Adoption of Its PCIe Retimers by Leading AI and Data Center Infrastructure Providers
December 9, 2025
Marvell Technology, Inc. Reports Third Quarter of Fiscal Year 2026 Financial Results
December 2, 2025
Marvell to Acquire Celestial AI, Accelerating Scale-up Connectivity for Next-Generation Data Centers
December 2, 2025
Marvell Extends Collaboration with Microsoft, Expanding Azure Global Cloud Security Services in Europe
December 1, 2025
Marvell Technology, Inc. Announces Conference Call to Review Third Quarter of Fiscal Year 2026 Financial Results
November 4, 2025